Clinical practice guidelines for rituximab treatment in children with steroid-sensitive nephrotic syndrome.

ABSTRACT:

Background

Steroid-sensitive nephrotic syndrome is a prevalent glomerular disease in children. The 2021 guidelines for glomerular disease management by Kidney Disease: Improving Global Outcomes and the 2023 recommendations for steroid-sensitive nephrotic syndrome management by International Pediatric Nephrology Association recommend rituximab for frequently relapsing nephrotic syndrome and steroid-dependent nephrotic syndrome in children. However, there is considerable variation in rituximab application, including administration timing, dose, frequency, concomitant medications, and follow-up schedules. In addition, rituximab use for nephrotic syndrome remains off-label in most countries.

Data sources

The "Pediatric Nephrology Committee of the Chinese Medical Doctor Associati

SUBMITTER: Shen Q 

PROVIDER: S-EPMC12380898 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature